SenoRx Board Appoints John T. Buhler as Chief Executive Officer and Member of Board of Directors

SenoRx, Inc. (Nasdaq:SENO) announced today that its Board of Directors appointed acting Chief Executive Officer John T. Buhler as the company's new Chief Executive Officer and a member of the Board of Directors. The appointment is effective immediately. As previously announced, SenoRx Chairman and Chief Executive Officer Lloyd H. Malchow passed away on March 14, 2010, while on a medical leave of absence. Mr. Buhler will now serve as SenoRx's President and Chief Executive Officer.

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor® vacuum-assisted breast biopsy system and Contura™ MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.           

The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605

CONTACT: SenoRx, Inc.

Lila Churney, Director of Investor Relations

949.362.4800 ext.132